The rate of death in this disease is so low you would have to do a trial size of thousands, if not hundreds of thousands, to achieve statistical significance in time to ventilation or death, even with a perfect cure.
HGEN leadership has vast experience in getting drugs through FDA trials and to market - they have clearly designed this trial to achieve EUA & eventual approval with as small of a sample size as possible, and it is working.